NEW YORK, February 22, 2017 /PRNewswire/ --
On Tuesday, February 21, 2017, the NASDAQComposite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com
Tandem Diabetes Care
San Diego, California headquartered Tandem Diabetes Care Inc.'s stock finished Tuesday's session 4.08% lower at $2.35 with a total volume of 238,586 shares traded. Tandem Diabetes Care's shares have advanced 4.44% in the past three months. The Company's shares are trading above its 50-day moving average by 0.21%. Shares of Tandem Diabetes Care, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have a Relative Strength Index (RSI) of 48.72. See our free and comprehensive research report on TNDM at:
C. R. Bard
Murray Hill, New Jersey headquartered C. R. Bard Inc.'s stock edged 0.34% higher, to close the day at $243.24. The stock recorded a trading volume of 559,059 shares. C. R. Bard's shares have gained 5.09% in the last one month, 12.73% in the previous three months, and 28.96% in the past one year. The Company's shares are trading 5.85% and 8.88% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, are trading at a PE ratio of 34.60. Additionally, the stock has an RSI of 73.13. BCR free research report PDF is just a click away at:
On Tuesday, shares in Laguna Hills, California headquartered Glaukos Corp. ended the session 0.04% lower at $45.60 with a total volume of 259,449 shares traded. Glaukos' shares have surged 18.63% in the last one month and 35.51% in the previous three months. Furthermore, the stock has rallied 172.56% in the past one year. Shares of the Company, which develops and commercializes products and procedures designed for the treatment of glaucoma, are trading at a PE ratio of 912.00. The stock is trading 18.90% above its 50-day moving average and 37.09% above its 200-day moving average. Moreover, the Company's shares have an RSI of 74.15. Sign up for your complimentary report on GKOS at:
On Tuesday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 769,695 shares, which was higher than their three months average volume of 565,670 shares. The stock ended the day 2.05% lower at $11.00. Shares of the Company, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, are trading at a PE ratio of 31.25. OraSure Technologies' stock has surged 28.96% in the last one month and 29.56% in the previous three months. Furthermore, the stock has rallied 76.00% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 20.72% and 39.10%, respectively. Furthermore, OraSure Technologies' shares have an RSI of 76.06.
On February 09th, 2017, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Register for free on Stock-Callers.com and download the latest research report on OSUR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All